Diagnostic efficacy of SonoVue

Area of Science:

• Cardiovascular Imaging
• Medical Ultrasound
• Pharmacology

Background:

• Suboptimal endocardial border delineation limits echocardiography in diagnosing ischemic heart disease.
• Second-generation ultrasound contrast agents aim to improve diagnostic accuracy.

Purpose of the Study:

• To evaluate the efficacy and safety of SonoVue compared to Albunex for contrast-enhanced echocardiography.
• To assess SonoVue's utility in diagnosing ischemic heart disease at rest and during pharmacologic stress.
• To determine SonoVue's effectiveness in evaluating various vascular territories.

Main Methods:

• Comparative study of SonoVue and Albunex in patients with suspected ischemic disease.
• Pharmacologic stress echocardiography with SonoVue.
• Assessment of SonoVue-enhanced power Doppler and harmonic contrast echocardiography for myocardial perfusion.
• Evaluation of SonoVue in carotid, intracranial, and renal artery imaging.
• Safety assessment in 1,406 patients.

Main Results:

• SonoVue significantly improved left-ventricular endocardial-border delineation score and contrast effect duration versus Albunex.
• SonoVue enhanced delineation at rest and during pharmacologic stress.
• Myocardial perfusion defect detection with SonoVue was comparable to SPECT imaging.
• SonoVue improved Doppler signal evaluation, especially for intracranial vessels.
• Adverse event rate was 10.4%, mostly mild and transient.

Conclusions:

• SonoVue is a safe and effective ultrasound contrast agent for improving echocardiographic assessment of ischemic heart disease.
• SonoVue enhances visualization of cardiac and vascular structures, aiding in diagnosis.
• Its performance is comparable to established imaging modalities for specific applications.